NICE blames Faslodex rejection on uncertainties in AZ data | InPharm

Links shared publicly online about this topic.

  • 52
    total visits

NICE blames Faslodex rejection on uncertainties in AZ data | InPharm

inpharm.com —

NICE has not recommended a high-dose form of AstraZeneca’s breast cancer drug Faslodex because of uncertainties over its cost-effectiveness

View full resource at inpharm.com

Tags: Cancer, Cancer Medication, Breast Cancer, Breast Cancer Medication, Drug, Pharma, Women's Health, AstraZeneca

  • Share

Most Recently Shared on August 23, 2011 at 11:46 am By:

pharmagossip Jack Friday - PharmaGossip

RT @Pharmafocus: #NICE blames Faslodex rejection on uncertainties in AZ data http://ow.ly/6aeSq #pharma

8 months ago...

Reply

Retweet

Favorite

Also Shared By:

Pharmafocus Pharmafocus

Advertisement